Checked.be
Active
BE 0822.147.452Private limited company
DR. DE CUYPER EVA
Dopheidestraat 7 ·3600 Genk, Belgium· 16 yrs active
Sector: Specialist medical practice
(86220)
Conclusion
DR. DE CUYPER EVA has been active since 2010 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €680k and a net result of €239k. Equity is growing by ~9.2% per year across the filed fiscal years. Its solvency ranks better than 73% of 16132 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is < 0.1% (very low).
Based on the State Gazette, CBE and 6 annual accounts.
Key figures
| Equity | €680k |
| Net result | €239k |
| Better than sector | 73% |
| Active | 16 yrs |
Financial profile
95
/ 100
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Health
98
Profitability
100
Solvency
100
Growth
78
Stability
100
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
Established
Founded in 2010, 16 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
98
/ 100
Excellent
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€65k
estimate, not credit advice
Score history
85
2020
100
2021
90
2022
100
2023
100
2024
98
2025
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 6.30 (≥ 1.5)
+10
Quick ratio
Quick ratio 6.30 (≥ 1.0)
+5
Leverage
Debt/equity 0.21 (< 1.0)
+10
Profitability
ROE 35% (≥ 10%)
+10
Interest coverage
Interest coverage 108.5× (≥ 3×)
+8
Profit trend
Net profit up YoY
+5
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview
Annual accounts filed on 27-08-2026 with the NBB · fiscal year 2025 · micro schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing
Equity: growth of ~9.2%/year over 6 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2025 · NACE 86, Human health activities · compared within the same schema type (micro schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 82.9% | 63.4% | |
| Net result | €239k | €62k | |
| Equity | €680k | €132k | |
| Gross operating margin | €390k | €116k | |
| Total assets | €819k | €286k |
€387k
+8.6%
20-25
€239k
+8.8%
20-25
€279k
+9.3%
20-25
€819k
-4.6%
20-25
€680k
-5.0%
20-25
€516k
-8.1%
20-25
€108k
+9.7%
20-25
€275k
+716.2%
20-25
€140k
-2.8%
20-25
€97k
+44.1%
20-25
€38k
-48.0%
20-25
6.30
-32.3%
20-25
6.30
-32.3%
20-25
82.9%
-0.4%
20-25
0.21
+2.3%
20-25
35.2%
+14.5%
20-25
29.2%
+14.0%
20-25
108.55
+30.0%
20-25
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Deposit | micro schema | micro schema | micro schema | micro schema | micro schema |
| Revenue | - | - | - | - | - |
| EBITDA | €387k | €356k | €276k | €88k | €132k |
| Net profit | €239k | €220k | €168k | €38k | €64k |
| Cash flow | €279k | €255k | €196k | €67k | €101k |
| Staff costs | - | - | - | - | - |
| Income taxes | €108k | €99k | €75k | €15k | €26k |
| Dividends | €275k | - | €34k | €245k | - |
| Total assets | €819k | €859k | €668k | €557k | €792k |
| Equity | €680k | €715k | €495k | €361k | €567k |
| Debt | €140k | €144k | €173k | €196k | €225k |
| of which ≤ 1y | €97k | €67k | €64k | €51k | €44k |
| of which > 1y | €38k | €74k | €109k | €144k | €180k |
| Working capital | €516k | €561k | €393k | €267k | €497k |
| Employees (FTE) | - | - | - | - | - |
Ratios (computed)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Current ratio | 6.30 | 9.31 | 7.10 | 6.24 | 12.18 |
| Quick ratio | 6.30 | 9.31 | 7.10 | 6.24 | 12.18 |
| Working capital ratio | 62.9% | 65.3% | 58.7% | 48.0% | 62.7% |
| Solvency | 82.9% | 83.3% | 74.1% | 64.9% | 71.7% |
| Debt / equity | 0.21 | 0.20 | 0.35 | 0.54 | 0.40 |
| Long-term debt ratio | 0.06 | 0.10 | 0.22 | 0.40 | 0.32 |
| Interest coverage | 108.55 | 83.47 | 52.06 | 12.81 | 16.94 |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| ROA | 29.2% | 25.6% | 25.1% | 6.9% | 8.1% |
| ROE | 35.2% | 30.8% | 33.8% | 10.6% | 11.3% |
| EBITDA margin | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days inventory (DSI) | - | - | - | - | - |
Balance-sheet composition 2025
Full annual accounts (22 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Balance sheet, Assets | ||||||
| TOTAL ASSETS | 20/58 | €819k | €859k | €668k | €557k | €792k |
| Fixed assets | 21/28 | €207k | €231k | €212k | €239k | €251k |
| Tangible fixed assets | 22/27 | €207k | €231k | €212k | €239k | €251k |
| Current assets | 29/58 | €613k | €628k | €457k | €318k | €541k |
| Amounts receivable within one year | 40/41 | €265k | €222k | €184k | €143k | €128k |
| Cash & bank | 54/58 | €314k | €344k | €243k | €169k | €357k |
| Balance sheet, Equity & liabilities | ||||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €819k | €859k | €668k | €557k | €792k |
| Equity | 10/15 | €680k | €715k | €495k | €361k | €567k |
| Contributions / capital | 10/11 | €12k | €12k | €12k | €12k | €12k |
| Reserves | 13 | €667k | €703k | €483k | €349k | €555k |
| Amounts payable | 17/49 | €140k | €144k | €173k | €196k | €225k |
| Amounts payable after one year | 17 | €38k | €74k | €109k | €144k | €180k |
| Amounts payable within one year | 42/48 | €97k | €67k | €64k | €51k | €44k |
| Trade debts payable within one year | 44 | €3k | €6k | €48 | €10k | €4k |
| Income statement | ||||||
| Gross operating margin | 9900 | €390k | €360k | €279k | €92k | €136k |
| Operating result | 9901 | €348k | €321k | €247k | €60k | €95k |
| Financial income | 75 | €3k | €2k | €210 | €1k | €2k |
| Financial charges | 65 | €4k | €4k | €5k | €7k | €8k |
| Result before taxes | 9903 | €347k | €319k | €242k | €54k | €89k |
| Income taxes | 67/77 | €108k | €99k | €75k | €15k | €26k |
| Net result for the period | 9904 | €239k | €220k | €168k | €38k | €64k |
| Result to be appropriated | 9905 | €239k | €220k | €168k | €38k | €64k |
Legal Structure
| NACE primary | Specialist medical practice(86220) |
| Legal form | Private limited company(610) |
| Incorporation | 11-01-2010 |
| Status | Active |
| Postal code | 3600 |
Establishment units
Dopheidestraat 7, 3600 Genk
since 20102.185.427.717
Real-estate footprint
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 71303B0044/00C026 | Flanders | 1,378 m² | 1 · 204 m² | 9.9 m · 2 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
Next filing, fiscal year 2026, expected by
2026
27-08
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema · 27 days late
2025
31-12
Financial
Highest result since 2020net €239k ▲8.8%
Operating result €348k, net result €239k, both a record.
28-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
31-12
Financial
Equity above €500kEq €715k ▲44.4%
5 profitable years in a row build equity to €715k.
28-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 28 days late
2023
29-06
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
31-12
Financial
Weakest financial yearnet €38k ▼39.8%
Net result drops to €38k, the lowest in the series; recovery starts the following year.
10-06
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2021
25-06
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2020
30-06
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
19-06
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema
2018
19-07
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema
2017
18-07
NBB filing
Annual accounts filed
fiscal year 2016 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 3 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
Specialist medical practice86220Other education85599
Names & trade names
| Legal nameNL | DR. DE CUYPER EVA |
Similar companies
ENDOCRINE UNIT
BE 0478.931.263 · Oudergem
Dermatoloog Raes
BE 0848.730.105 · Hoogstraten
Dr. H. Van Kerckhoven - Anesthesie
BE 0518.987.315 · Sint-Niklaas
Dokter SCHUMMER
BE 0444.538.825 · Diest
DOKTER DAVID VANWYNSBERGHE, OPHTALMOLOOG
BE 0832.144.390 · Gent